Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma With Renal Dysfunction in Real-World: A Non-interventional Prospective Multicenter Observational Study
Conditions
Interventions
Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens
Start Date
October 1, 2022
Primary Completion Date
September 30, 2024
Completion Date
September 30, 2025
Last Updated
September 30, 2022
NCT05259553
NCT06348147
NCT03733691
NCT05558319
Lead Sponsor
The First Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions